Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

FES Cycling With BFR in the Spinal Cord Injury Population

8 maggio 2026 aggiornato da: Dr. B. Catharine. Craven

Assessing the Safety and Feasibility of Functional Electrical Stimulation Cycling Coupled With Blood Flow Restriction in a Spinal Cord Injury Population

Cardiometabolic Disease (CMD) is the silent killer within the spinal cord injury/disease (SCI/D) population. Many SCI/D patients' initial CMD presentation is with a heart attack, stroke, or sudden cardiac death, highlighting the need for interventions to reduce CMD risk. CMD contributes to 46% of deaths, with 30-50% of the SCI/D population living with undiagnosed CMD. Treating CMD risk is more challenging in the SCI/D population due to prolonged inactivity, inability to exercise, and excessive caloric intake to expenditure ratio. Identifying accessible and inclusive strategies to combat CMD risk in the SCI/D population is a compelling and urgent health priority.

Blood flow restriction (BFR) exercise involves applying inflatable cuffs to the proximal end of an individual's limbs. Changes to the amount of blood flowing into and out of the limb lead to a low oxygen environment within the limb, shifting the way the muscles can produce the energy required to function, increasing the benefits of low- and moderate-intensity exercise. Coupling BFR with Functional electrical stimulation cycling (FES-cycling), a commonly used rehabilitation tool within the SCI population, could improve FES-cycling's short- and long-term benefits without reducing the accessibility and inclusiveness of long-term exercise prescription. Although preliminary BFR research in the SCI/D has identified positive muscular improvements, whether FES-cycling coupled with BFR can be safely prescribed or feasibly implemented long-term within the SCI/D population is unknown.

The proposed project aims to determine the safety and feasibility of FES-cycling coupled with BFR for 20 minutes of moderate-intensity exercise among adults with chronic spinal cord injury/disease (SCI/D). The research team aims to implement pre-test, eight exercise sessions, and post-test across 6-weeks. Criteria for success include no adverse or severe adverse events not alleviated by ceasing exercise (safety), a 1 to 8 ratio of participants screened to participants eligible (recruitment success), and participants successfully completing all exercise sessions (participant retention).

Panoramica dello studio

Stato

Reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

Background Spinal cord injury/disease (SCI/D) is a highly debilitating condition that results in motor, sensory, autonomic, and autoimmune impairments, which dramatically alters the individual's mobility, life, and health. Following injury, the individual's health is compromised by their primary impairment and secondary health conditions. Cardiometabolic Disease (CMD) refers to a collection of interrelated conditions (e.g., insulin resistance, chronic inflammation, and obesity) that increase the risk of cardiovascular and metabolic disease. CMD disease contributes to 46% of deaths within the SCI/D population. Currently, limited rehabilitation strategies exist that can effectively combat CMD risk factors among individuals living with an SCI/D. Therefore, identifying accessible, inclusive, and safe rehabilitation strategies to combat CMD risk among individuals living with an SCI/D is a compelling and urgent health priority.

Study Aim and Rationale The proposed project aims to investigate the safety and feasibility of functional electrical stimulation cycling (FES-Cycling) coupled with blood flow restriction (BFR). Preliminary studies examining BFR exercise within SCI/D individuals have reported positive findings. However, the pioneering BFR exercise research has not prescribed moderate-intensity aerobic exercise that mirrors the SCI/D weekly exercise guidelines. Therefore, whether BFR can be tolerated safely and practically in the SCI/D population is unknown.

Methods The proposed pilot study will utilize a convergent mixed methods approach and implement a pretest-post test quasi-experimental design. Six adults (18-75yrs) with chronic (>1yr) SCI/D will be recruited to participate in two testing sessions (pre/post), four FES-Cycling exercise sessions, and four FES-cycling coupled with BFR sessions across six weeks. Measures of safety, participant recruitment, and retention will be collected. A criterion of success will be developed for each measure. Descriptive statistics will be calculated and compared to the prior-defined success criterion. Deductive and inductive content analysis will assess participant feedback regarding exercise modality and protocol implementation.

Anticipated Results The research team expects to accomplish the success criteria for all measurement categories based on the existing evidence across the domains of FES-cycling and BFR exercise within SCI/D. Analysis of participant feedback will direct future protocol development and BFR prescription parameters.

Conclusions The proposed project is the first step towards developing a low-cost, highly accessible exercise accessory that could potentially maximize the physiological yield of aerobic and resistance exercise, increasing the potential protective abilities of exercise against CMD risk.

Tipo di studio

Interventistico

Iscrizione (Stimato)

6

Fase

  • Fase 1

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Backup dei contatti dello studio

Luoghi di studio

  • Canada
    • Ontario
      • Toronto, Ontario, Canada, M4G 3V9
        • Reclutamento
        • Lyndhurst Centre
        • Contatto:
        • Contatto:
        • Investigatore principale:
          • B.Catharine Craven, MD
        • Sub-investigatore:
          • Kristin Musselman, Ph.D

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Adulto
  • Adulto più anziano

Accetta volontari sani

No

Descrizione

Inclusion Criteria:

  • Adult (≥ 18 to ≤ 75yrs)
  • Male or female
  • Chronic Injury (>1yr)
  • Diagnosis of SCI at levels between C5 to T10 (AIS A-D) with traumatic or non-traumatic etiology.
  • ≥3 Cardiometabolic risk parameters

Exclusion Criteria:

  • A prior or current history of venous thromboembolism
  • Pressure injury of the pelvis, mid to upper thigh region, or foot
  • Managing a lower limb fracture
  • Any history of embolic stroke
  • Myocardial infarction
  • Current untreated hypertension
  • Language, psychiatric, cognitive, or communicative disability (e.g., traumatic brain injury) that compromises the participant's autonomy to voluntarily join the study, follow its instructions and/or operate the device.
  • Current alcohol or street drug use disorder.
  • Current use of an anticoagulant medication.
  • Frequent episodes of autonomic dysreflexia unresponsive to therapy (e.g., 3-5 times a week).
  • Unresolved deep vein thromboembolism (VTE) in the past six months.
  • Severe spasticity preventing the necessary range of motion for cycling.
  • Active implantable medical device (e.g., pacemaker, ITB pump).
  • Inability to provide informed consent.
  • Severe active concurrent medical conditions (e.g., skin or respiratory infections, lung, pressure sores).
  • Unstable spine or unhealed limbs or pelvic fractures.
  • Active heterotopic ossification interfering with the lower extremity range of motion.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Altro
  • Assegnazione: Non randomizzato
  • Modello interventistico: Assegnazione incrociata
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore attivo: Functional Electrical Stimulated Cycling
Four FES-Cycling exercise sessions. Participants will complete 20 minutes of exercise two times a week for 2 weeks.
Altro: Functional Electrical Stimulated Cycling
Electrical impulses will be sent to the muscles of the lower leg during cycling to facilitate muscular contractions.
Comparatore attivo: Functional Electrical Stimulated Cycling with Blood Flow Restriction
Four FES-Cycling with BFR exercise sessions. Participants will complete 20 minutes of exercise two times a week for 2 weeks.
Altro: Functional Electrical Stimulated Cycling
Electrical impulses will be sent to the muscles of the lower leg during cycling to facilitate muscular contractions.
Dispositivo: Blood Flow Restriction
Blood Flow Restriction (BFR) exercise is a training method where a specialized cuff or band is applied to the top of a limb (arm or leg) to partially restrict blood flow during exercise.
Altri nomi:
  • KAATSU

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Participant Retention
Lasso di tempo: Six weeks - From enrollment to the end of the exercise protocol.
For a long-term clinical trial spanning 3 to 6 months of data collection per participant, the research team would estimate an approximate retention rate of 80%. Therefore, our criteria for successful participant retention as a feasibility assessment is having a maximum of two recruited participants who do not complete the 4-week protocol.
Six weeks - From enrollment to the end of the exercise protocol.
Safety - Skin Checks
Lasso di tempo: 6 weeks
Pre/post-session skin checks will be performed and findings recorded as a metric of safety.
6 weeks
Safety - Adverse Event Report
Lasso di tempo: 6 weeks
Any adverse or serious adverse events will be reported as per the hospital policy.
6 weeks
Recruitment Rate
Lasso di tempo: 2 to 3 months, depending on how successful the recruitment process is.
Our criteria for success in recruiting six participants is 2 to 3 months. The time taken to successfully recruit 6 participants will be reported.
2 to 3 months, depending on how successful the recruitment process is.
Change in CMD Risk Profile - Lipid Profile
Lasso di tempo: Six weeks - From enrollment to the end of the exercise protocol.
Participants will have a blood draw pre- and post-exercise intervention. Participants' fasting lipid profiles will be assessed. All aspects will be reported as millimoles per litre (mmol/L) and will involve: total cholesterol, low-density cholesterol, high-density cholesterol and triglycerides.
Six weeks - From enrollment to the end of the exercise protocol.
Participant Perspectives and Experience
Lasso di tempo: 6 weeks
Participant satisfaction is fundamental to implementing a successful long-term clinical trial. The interview guide will use a combination of structured and semi-structured interview techniques during the follow-up session to gain the participant's perspectives on the implemented protocol, elements they enjoy and elements they did not. After study completion, one-on-one semi-structured interviews (in-person or via MS Teams) lasting approximately 45-60 minutes will be conducted to explore participants' perceptions of recruitment approaches, elements they enjoy and elements they did not. Interviews will be voiced record and word for word transcribed for batch analysis at the completion of the entire study. This will allow us to look beyond the efficacy of the novel exercise technique and consider its level of practicality, acceptability and scalability within the SCI population. Participants that choose to withdraw will not be interviewed.
6 weeks
Safety - Heart Rate
Lasso di tempo: Six weeks - From enrollment to the end of the exercise protocol.
Heart rate will be measured at fixed time points pre- and post-session and continuously throughout the exercise period. Heart Rate will be recorded as beats per minute.
Six weeks - From enrollment to the end of the exercise protocol.
Safety - Blood Pressure
Lasso di tempo: Six weeks - From enrollment to the end of the exercise protocol.
Blood pressure will be recorded at a fixed time point pre- and post-session, and at two-minute increments throughout the exercise period. Systolic and Diastolic blood pressure will be reported as millimetres of mercury.
Six weeks - From enrollment to the end of the exercise protocol.
Safety - Oxygen Saturation
Lasso di tempo: Six weeks - From enrollment to the end of the exercise protocol.
Oxygen saturation will be collected at a fixed time point pre- and post-session, and at two-minute increments throughout the exercise period. Oxygen saturation will be measured as a percentage of available hemoglobin binding sites occupied by oxygen.
Six weeks - From enrollment to the end of the exercise protocol.
Safety - Rating of Perceived Exertion and Discomfort.
Lasso di tempo: Six weeks - From enrollment to the end of the exercise protocol.
Ratings of perceived exertion and discomfort will be recorded at two-minute increments during the exercise period and at a fixed time point post-exercise. Both perceived exertion and discomfort will be rated on a scale from 0 to 10.
Six weeks - From enrollment to the end of the exercise protocol.
Change in CMD Risk Profile - C-Reactive Protein
Lasso di tempo: Six weeks - From enrollment to the end of the exercise protocol.
Participants will have a blood draw pre- and post-exercise intervention. Participants' C-Reactive Protein levels will be reported as milligrams per litre (mg/L).
Six weeks - From enrollment to the end of the exercise protocol.
Change in CMD Risk Profile - Hemoglobin A1c
Lasso di tempo: Six weeks - From enrollment to the end of the exercise protocol.
From the Pre-/post-intervention blood draws participant's Hemoglobin A1c will be reported as a percentage (%).
Six weeks - From enrollment to the end of the exercise protocol.
Change in CMD Risk Profile - Fasted Plasma Glucose
Lasso di tempo: Six weeks - From enrollment to the end of the exercise protocol.
From the pre-/post-intervention blood draws, participants' Fasted Plasma Glucose will be reported as millimoles per litre (mmol/L).
Six weeks - From enrollment to the end of the exercise protocol.
Change in CMD Risk Profile - Waist Circumference
Lasso di tempo: Six weeks - From enrollment to the end of the exercise protocol.
Pre- and Post-intervention participants' waist circumference will be measured and reported (cm)
Six weeks - From enrollment to the end of the exercise protocol.
Change in CMD Risk Profile - Body Mass Index
Lasso di tempo: Six weeks - From enrollment to the end of the exercise protocol.
Pre- and Post-intervention participants height (cm) and weight (kg) will be recorded and Body Mass index calculated and reported (kg/m²)
Six weeks - From enrollment to the end of the exercise protocol.

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Dr. B. Catharine. Craven

Collaboratori

CAN-TAP-TALENT (CIHR Stream)

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

15 giugno 2026

Completamento primario (Stimato)

1 gennaio 2027

Completamento dello studio (Stimato)

30 settembre 2027

Date di iscrizione allo studio

Primo inviato

14 aprile 2026

Primo inviato che soddisfa i criteri di controllo qualità

8 maggio 2026

Primo Inserito (Effettivo)

14 maggio 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

14 maggio 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

8 maggio 2026

Ultimo verificato

1 maggio 2026

Maggiori informazioni

Termini relativi a questo studio

Parole chiave

Termini MeSH pertinenti aggiuntivi

Altri numeri di identificazione dello studio

  • 25-5288

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

Summary data of the primary variables

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Prove cliniche su Lesioni del midollo spinale

Cerca prove simili

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

CROs by country

CROs in Georgia

Condizioni

Malattie rare

Interventi farmacologici

Supplementi dietetici

Sponsor / Collaboratori

Sedi

Sottoscrivi